News
Start-up raises US$500K in angel funding in bid to “reimagine” women’s wellness
hey freya aims to improve accessibility to naturopathic care and help women achieve optimal health
The US women’s health brand hey freya has raised US$500,000 in angel funding to “reimagine” women’s wellness.
The start-up, which develops health tests and supplements for women, aims to improve accessibility to naturopathic care and help women achieve optimal health.
Their adaptogenic supplements and multi-vitamin products promise to target symptoms caused by stress and burnout in women and help women restore their energy, sleep and balance.
“There is a lack of accessible, high-quality, evidence-based solutions currently available to women,” explained Helkin Berg, co-founder and CEO of hey freya.
“Often dismissed by their doctors, women are turning elsewhere to understand what’s going on with their health, and to solve it. That’s why we founded hey freya.
“We believe that taking away the barrier of exhaustion currently plaguing women can make them unstoppable again, and that access to care and feeling well is imperative to the future of activism.”
The funding marks an exciting chapter in hey freya’s journey, said Berg.
“This raise has underscored that even against the backdrop of the current market, there is an incredible appetite for a new solution created by women, for women,” she said.
“We’re honoured to be trusted with this undertaking and these funds will help us get to the next phase of our mission.”
According to the founder, the start-up will use the funds to launch its naturopathic product line, explore clinical trials and support ongoing machine learning research with its partner, Northeastern University, on cortisol and women’s health.
Vanessa Loder, co-founder of Goddess Fun+d, who supported the funding round, said: “hey freya’s mission and team aligns so well with our own experiences and purpose.
“We’re thrilled to support the revolutionary progress they’re making in women’s health to take the burden off of women by offering accessible, evidence-backed, health and wellness solutions.”
To receive the Femtech World newsletter, sign up here.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







2 Comments